We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

39 hedge funds and large institutions have $3.91M invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2014 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 4

30% more funds holding

Funds holding: 30 → 39 (+9)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

7% less capital invested

Capital invested by funds: $4.21M → $3.91M (-$296K)

Holders
39
Holders Change
+9
Holders Change %
+30%
% of All Funds
1.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
5
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
+$442K
2
CS
Credit Suisse
Switzerland
+$156K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$126K
4
CCB
Cutter & Co Brokerage
Missouri
+$84.6K
5
HighTower Advisors
HighTower Advisors
Illinois
+$32.4K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$254K
2
MFBTD
MB Financial Bank - Trust Department
Illinois
-$27.4K
3
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$13K
4
CIC
Carnegie Investment Counsel
Ohio
-$10K
5
PAG
Private Advisor Group
New Jersey
-$6.86K
Name Holding Trade Value Shares
Change 		Change in
Stake
MFBTD
26
MB Financial Bank - Trust Department
Illinois
$8K -$27.4K -30,000 -75%
EC
27
Estate Counselors
Wisconsin
$8K – – –
Morgan Stanley
28
Morgan Stanley
New York
$4K -$640 -700 -13%
GT
29
Glenmede Trust
Pennsylvania
$4K – – –
NPC
30
National Planning Corporation
California
$3.38K +$3.77K +4,128 New
Wells Fargo
31
Wells Fargo
California
$3K – – –
Citigroup
32
Citigroup
New York
$2K – – –
TIM
33
Tortoise Investment Management
New York
$2K – – –
LTFS
34
Ladenburg Thalmann Financial Services
Florida
$1K – – –
FWM
35
Focused Wealth Management
New York
$1K +$1.56K +1,705 New
LS
36
Lupo Securities
Illinois
$640 +$731 +800 New
BRWA
37
B. Riley Wealth Advisors
Florida
$11 – – –
Cambridge Investment Research Advisors
38
Cambridge Investment Research Advisors
Iowa
– -$13K -12,664 Closed
CIC
39
Carnegie Investment Counsel
Ohio
– -$10K -10,000 Closed
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
– -$5K -5,000 Closed
HNB
41
Huntington National Bank
Ohio
– +$183 +200 New
1
2

PVCT Hedge Fund Activity: Q4 2014 in Review

39 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q4 2014, worth a combined $3.91M — down 7% from $4.21M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new PVCT positions and 4 closed out — a net gain of 10 holders — while 5 added to existing stakes and 5 trimmed.

The largest buyer was Virtu KCG Holdings, adding an estimated $442K. The largest seller was Goldman Sachs, cutting an estimated $254K.

  • 39 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q4 2014, up from 30 in Q3 2014.
  • Funds reported $3.91M of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q4 2014, down 7% quarter-over-quarter.
  • 14 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q4 2014 and 4 closed out, a net change of +10 holders.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q4 2014 was Virtu KCG Holdings, an estimated $442K added.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q4 2014 was Goldman Sachs, an estimated $254K sold.

Based on aggregated 13F filings for Q4 2014.